No Data
No Data
MannKind Initiated at Buy by Rodman & Renshaw
MannKind Initiated at Buy by Rodman & Renshaw
Express News | Rodman & Renshaw Initiates Coverage On MannKind With Buy Rating, Announces Price Target of $8
Rodman & Renshaw Initiates MannKind(MNKD.US) With Buy Rating, Announces Target Price $8
Rodman & Renshaw analyst Elemer Piros initiates coverage on $MannKind(MNKD.US)$ with a buy rating, and sets the target price at $8.According to TipRanks data, the analyst has a success rate of 37.3% a
Inhale-3 Study Results to Be Presented During a 90-Minute Symposium on Saturday, June 22 at the American Diabetes Association's 84th Scientific Sessions
17-week endpoint results comparing Afrezza head-to-head with multiple daily injections (MDI) and insulin pumps INHALE-3 Study Protocol Chair Dr. Irl. B. Hirsh joined by investigational team to deliver
Express News | Pulmatrix Enters Cross License Agreement With MannKind To Use Cricket Inhalation Device For Delivery Of PUR3100 And Other Dry Powder Formulations For Neurological Diseases
Express News | Pulmatrix Inc - as Part of Transaction, MannKind Will Assume Lease of Bedford, Mass., R&D Facility
No Data